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The system described here allows the expression of
protein fragments into a solvent-exposed loop of a carrier
protein, the b-lactamase BlaP. When using Escherichia
coli constitutive expression vectors, a positive selection of
antibioresistant bacteria expressing functional hybrid
b-lactamases is achieved in the presence of b-lactams
making further screening of correctly folded and secreted
hybrid b-lactamases easier. Protease-specific recognition
sites have been engineered on both sides of the b-lactamase
permissive loop in order to cleave off the exogenous
protein fragment from the carrier protein by an original
two-step procedure. According to our data, this approach
constitutes a suitable alternative for production of diffi-
cult to express protein domains. This work demonstrates
that the use of BlaP as a carrier protein does not alter
the biochemical activity and the native disulphide bridge
formation of the inserted chitin binding domain of the
human macrophage chitotriosidase. We also report that
the b-lactamase activity of the hybrid protein can be used
to monitor interactions between the inserted protein
fragments and its ligands and to screen neutralizing
molecules.
Keywords: b-lactamase/antibodies/high through put
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Introduction
Many Escherichia coli expression vectors are available to
produce and to purify proteins fused to affinity tags, such
as the Schistosoma japonicum glutathione S-transferase
(GST), the E. coli maltose binding protein, the E. coli
thioredoxin etc (LaVallie and McCoy, 1995; Tsunoda et al.,
2005). All these systems allow the subsequent proteolytic
cleavage of the fusion protein to separate the protein of
interest from the affinity tags (LaVallie and McCoy, 1995;
Tsunoda et al., 2005). But a common feature of these
systems is the limited utility of the affinity tag in the bio-
chemical characterisation of the studied protein. This work
describes new opportunities by using the Bacillus licheni-
formis b-lactamase BlaP as a protein carrier and a reporter
enzyme.
BlaP is an active-serine enzyme belonging to class A of
b-lactamases (Matagne et al., 1999). Class A b-lactamases
share a similar three-dimensional structure characterised by
all a and a/b domains (Moews et al., 1990; Fonze´ et al.,
1995, 2002). This enzyme is a natural proteases-insensitive
protein adapted to the presence of various and numerous pro-
teases that are co-expressed by B. licheniformis (File´e et al.,
2002; Brans et al., 2004; Veith et al., 2004). Previously, we
identified a common permissive insertion site in class A
b-lactamases that is located in a solvent-exposed loop far
away from the active site. This position limits interferences
between the biological activities of the inserted polypeptide
and the carrier protein (Hallet et al., 1997; Ruth et al., 2005;
Chevigne´ et al., 2007). We demonstrated that small peptides
(Ruth et al., 2005), random protein fragments (Chevigne´
et al., 2007) and protein-binding motifs (Vandevenne et al.,
2007) can be accommodated in this loop without losing the
b-lactamase activity of the carrier protein. Moreover, we
showed that these hybrid proteins can be expressed at the
surface of phage fdTet in fusion with the minor coat protein
pIII and selected for their affinities towards specific targets
(Chevigne´ et al., 2007). This new approach for displaying
polypeptides is named b-lactamase hybrid protein technol-
ogy (BHP) for bifunctional hybrid proteins.
In a recent report, we described the insertion of the chitin
binding domain (CHBD) of the human macrophage chitotrio-
sidase into BlaP (Vandevenne et al., 2007). CHBD is a
protein domain of 73 residues that promotes binding to inso-
luble chitin. Three disulphide bridges have been reported as
essential for the chitin binding activity (Tjoelker et al., 2000;
Ujita et al., 2003). The BlaPCHBD construct behaved as a
soluble chimeric protein that conserves both the chitin-
binding and the b-lactamase activities of the related native
proteins. The biochemical and biophysical properties of this
protein have been studied and these results have contributed
to a better understanding of the reciprocal effects between
the carrier protein and the inserted protein fragment
(Vandevenne et al., 2007).
In this work, we have engineered the permissive loop of
the b-lactamase BlaP by the introduction of two thrombin
(Thb)-cleavage sites surrounding the insertion site. We
demonstrate here that the hybrid protein BlaP Thb/CHBD/
Thb remains bifunctional and that the inserted polypeptide
can be separated from its carrier protein without losing its
biochemical properties. As a result, this approach has facili-
tated the high and soluble production of this small mamma-
lian polypeptide, usually difficult to produce in E. coli.
A relevant application has been reported where the b-lactamase
activity of the hybrid protein was used to study the inter-
action between CHBD and chitin. Finally, it is also shown
that bifunctional hybrid b-lactamases can be used in the
screening of neutralizing agents.
Methods
Construction of pNY02 and pNY03
The synthetic gene fragment encoding two contiguous
thrombin-cleavage sites was obtained by annealing the comp-
lementary oligonucleotides Thbþ (50-CTGGTTCCGCG
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ACGCGGAACCAG-30). In this construction, the dipeptide
Pro-Glu separates the proteolytic clivage sites and permits to
create a SmaI restriction site (CCC-GGG) in the nucleotidic
sequence. The annealed oligonucleotides were successively
phosphorylated using T4 polynucleotide kinase and purified
on a QiaquickTM removal kit (Qiagen). The gene fragments
were finally ligated into the SmaI-digested and dephosphory-
lated pNY01 (Chevigne´ et al., 2007) to yield pNY02.
The gene fragment coding for CHBD was PCR amplified
using Pfu DNA polymerase with primers CHBDþ
(50-GGTAGCGGACCAGAGCTTGAAGTTCCTAAACCAG
GACAGCCCTCT-30) and CHBD2 (50-GTGGGGTCCATTC
CAGGTACAACATTTGCAGGAGTTGCTGAACACCAGAC
C-30). The PCR products were successively purified on a
GFXTM gel band purification kit (Amersham Biosciences,
UK), phosphorylated using T4 polynucleotide kinase and
purified again on a GFXTM gel band purification kit before
to be cloned into the SmaI-digested and dephosphorylated
pNY02 to yield pNY03.
Hybrid b-lactamase purification
To achieve production of the hybrid b-lactamases harbouring
a polyhistidine tag, E. coli JM109 transformed with pNY02
or pNY03 were grown in Terrific Broth supplemented with
75 mg/ml spectinomycin and 10 mg/ml ampicillin at 378C.
Cells from an overnight culture (1 l) were harvested by cen-
trifugation (9000g for 15 min) and resuspended in 40 ml of
TES (20% sucrose, 30 mM Tris–HCl, 5 mM EDTA, pH 8)
at 378C. The bacterial suspension was placed under stirring
at 378C for 10 min. Cells were harvested by centrifugation
(9000g for 15 min) and the pellet resuspended in 100 ml of
5 mM MgSO4 at 48C. The bacterial suspension was stirred at
48C for 10 min. The supernatant containing the periplasmic
proteins was harvested by centrifugation (13 000g for
20 min) and diluted with three volumes of 50 mM phosphate
(pH 7.4). The periplasmic proteins were loaded on a
HisTrapTM Chelating HP column (GE healthcare) equili-
brated in 50 mM phosphate (pH 7.4). The column was suc-
cessively washed with 2 M NaCl and 50 mM phosphate (pH
7.4) supplemented with 10 mM Imidazole. The hybrid pro-
teins were eluted by an imidazole linear gradient (10–
500 mM) in 50 mM phosphate (pH 7.4). Fractions containing
the purified hybrid proteins were pooled and dialysed against
phosphate-buffered saline (PBS) (50 mM phosphate,
150 mM NaCl, pH 7.4).
Quantitation of the sulphhydryl groups with DTNB
Ellman’s reagent, 5,50-Dithio-bis(2-nitrobenzoic acid),
DTNB (Ellman, 1959), was used for the determination of
free thiols with glutathione as a standard. BlaP Thb/SmaI/
Thb was used as a negative control. All measurements were
performed by incubating samples in urea 6 M during 2 h to
expose non-accessible cysteines in the native structures.
Proteins and DTNB (1 ¼ 13 600 M21 cm21) concentrations
were, respectively, 5 mM and 10 mM. Hundred microlitres of
protein or glutathione solutions were incubated during 5 min
with 900 ml of DTNB solution. Absorbance of samples was
measured at 420 nm.
Thrombin cleavage
Thrombin (Sigma, Washington DC, USA) cleavage was per-
formed in PBS supplemented with 2.5 mM CaCl2 at 208C
under overnight agitation. Five units of protease were used to
digest 1 mg of protein in a final volume of 1 ml. We avoided
the use of 2-mercaptoethanol when working with BlaP Thb/
CHBD/Thb to prevent reduction of the native disulphide
bonds in CHBD. To eliminate the N- and C-terminal frag-
ments of the b-lactamase BlaP which remain bound by non-
covalent interactions, the sample was loaded on HisTrapTM
Chelating HP column. Purified CHBD was collected in the
flow through.
Chitin binding assay
Identical amounts (70 pmol) of BlaP Thb/SmaI/Thb, BlaP
Thb/CHBD/Thb and ChBD were incubated during 2 h with
25 mg of insoluble chitin (Sigma) in a final volume of
300 ml of 50 mM sodium phosphate buffer (pH 7.5) in the
presence or in the absence of 50 mM 1,4-Dithio-DL-threitol
(DTT). The solutions were centrifuged at 13 000 rpm during
10 min to separate the supernatants containing unbound pro-
teins from the pellet containing chitin with the captured pro-
teins. The free proteins in the supernatants were analysed by
SDS–PAGE and compare with the supernatants before
addition of chitin.
Kr determination
Binding assays were conducted as follows: various concen-
trations of the chimeric protein (25 nM to 3 mM) were incu-
bated in the presence of 10 mg of chitin in final volume of
500 ml of 50 mM sodium phosphate buffer, 150 mM NaCl,
pH 7.5 at 228C with continual mixing. The mixtures were
centrifuged at 48C for 15 min at 13 000 rpm and the super-
natant containing the free protein was collected. The free
protein concentration was determined using the reporter
b-lactamase activity. The amount of bound protein was cal-
culated as the difference between the initial protein concen-
tration and the free protein concentration after binding. The
relative equilibrium association constants (Kr) was deter-
mined by the method described by Gilkes et al. (Gilkes
et al., 1992) using the following equation:
½B ¼ ½N0Ka½F
1 þ aKa½F :
Where [B] is the concentration of bound ligand (moles. g
chitin21), [F] the concentration of free ligand (molar), [N0]
the concentration of binding site in the absence of ligand, a
the number of lattice units occupied by a single ligand mol-
ecule and Ka the equilibrium association constant
(litres.mol21). Ka value cannot be isolated from this equation
but the relative equilibrium association constant, Kr (litres.g
chitin21) is defined as:
Kr ¼ ½N0Ka:
Electrospray ionisation mass spectrometry
Purified CHBD was concentrated on a bed of PEG 20 000 to
obtain a concentration of 0.25 mg/ml. Classical concentrating
systems were avoided to prevent adsorption of the protein
on membranes. Aggregation was observed at CHBD
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concentrations .0.25 mg/ml. Before analysing the protein
by mass spectrometry, the protein was dialysed against
50 mM ammonium acetate (pH 7).
Anti-CHBD antibodies
A polyclonal anti-CHBD antiserum was obtained by immu-
nizing one New Zealand white rabbit with four injections of
purified CHBD (Centre d’Economie Rurale et
d’Hormonologie de Marloie).
Kinetic studies
The kinetic parameters of the purified bifunctional hybrid
b-lactamases were determined using nitrocefin in 50 mM
phosphate buffer at pH 7. The initial rate of hydrolysis was
monitored at 482 nm. The Km and kcat values were calculated
by fitting the data to the Henri-Michaelis equation and its
linearised form according to the Hanes transformation (Fre`re,
1973).
Western blot analysis
Purified proteins (500 ng) were denatured at 1008C in the
presence of denaturing buffer and separated by SDS–PAGE
(15%). The proteins were electroblotted onto a polyvinyli-
dene difluoride membrane. Immunoblot analyses using poly-
clonal preimmune or anti-CHBD rabbit sera were carried out
and rabbit antibodies were detected with ECL kit
(Amersham Biosciences) by using goat horseradish
peroxidase-conjugated anti-rabbit antibodies.
Seroneutralisation assays
The experiments were performed in PBS (50 mM sodium
phosphate, 150 mM NaCl, pH 7.4). Identical quantities
(20 ng) of proteins (BlaP Thb/SmaI/Thb and BlaP Thb/
CHBD/Thb) were preincubated or not with various dilutions
of preimmune or anti-CHBD sera for 1 h before to be incu-
bated during 2 h with 10 mg of insoluble chitin (Sigma). All
the incubations were performed at room temperature. The
solutions were centrifuged at 13 000g during 10 min to sep-
arate the supernatant containing unbound proteins from the
pellet containing chitin with the captured proteins. The
pellets were washed three times with 1 ml of wash buffer
(50 mM phosphate, 500 mM NaCl, pH 7.4) and then incu-
bated in the presence of 1 ml of 100 mM nitrocefin a chromo-
genic b-lactam at 258C for 30 min. Then the suspensions
were rapidly filtered through a 0.22 mm cut-off filter and the
absorbances of the hydrolysis products were measured at
482 nm to determine the chitin immobilised b-lactamase
activity.
Interaction of phage particles with chitin
Production and purification of phage particles harbouring the
bifunctional hybrid protein or the parental b-lactamase were
performed as described in our previous work (Chevigne´
et al., 2007). Interaction with phage particles was performed
as follow: 100 ml of the phage particles solution (DO260nm ¼ 5)
in 500 ml final volume of 50 mM Tris buffer (pH 7.5) were
incubated 2 h with 10 mg of insoluble chitin (Sigma). The
solutions were centrifuged at 13 000 rpm during 10 min to
separate the supernatant containing unbound protein from the
pellet containing chitin with the captured protein. The pellets
were washed three times with 50 mM Tris buffer, 500 mM
NaCl and then incubated in the presence of 100 mM
nitrocefin for 5 min at 258C. Then the suspension was
rapidly filtered, and the absorbance of the hydrolysis product
was measured at 482 nm.
Detection of fungal chitin
A colony of Candida albicans (ATCC 10231) was inoculated
into 30 ml of YPD medium containing 2% dextrose and
growth at 288C for 20 h. To detect chitin, 4.8 ml of this
culture (DO600 nm ¼ 0.5) was centrifuged at 8000 rpm. The
pellet washed twice with 50 mM sodium phosphate buffer
(pH 7.5) and then resuspended in 500 ml of phosphate buffer
containing 5 pmol of BlaP or BlaPChBD. The reaction
mixture was incubated for 2 h at 48C under continuous
mixing. The cell suspensions were centrifuged at 8000 rpm
during 10 min to separate the supernatant containing
unbound protein from the pellet containing chitin with the
captured protein. The pellets were washed three times with
50 mM sodium phosphate buffer, 0.2% Tween and then incu-
bated in the presence of 100 mM nitrocefin for 35 min at
258C. Then the suspension was rapidly filtered, and the
absorbance of the hydrolysis product was measured at
482 nm.
Results
PNY01 is an E. coli plasmid that allows a high constitutive
periplasmic expression of the engineered class A BlaP/SmaI
b-lactamase (Vandevenne et al., 2007). The gene encoding
BlaP/SmaI was obtained by insertion of two codons
(CCC-GGG), corresponding to a SmaI restriction site and
coding for the dipepetide Pro-Gly, between residues Asp211
and Lys212 of the BlaP b-lactamase. This plasmid was
further modified by insertion into the SmaI restriction site of a
nucleotidic sequence encoding two adjacent thrombin-
cleavage sites characterised each by the consensus peptidic
sequence ‘Leu-Val-Pro-Arg-Gly-Ser’ to give pNY02
(Fig. 1A). PNY02 leads to the production of the BlaP Thb/
SmaI/Thb b-lactamase (Fig. 1B). In this construction, the
thrombin-cleaveage sites are spaced by the Pro-Gly dipeptide,
allowing a re-introduction of a SmaI restriction site. This site
was subsequently used to clone the gene fragment encoding
the CHBD of the human macrophage chitotriosidase Chit1
(residues Pro398 to Asn466) to give pNY03 (Fig. 1A). This
plasmid allows the production of the BlaP Thb/CHBD/Thb
b-lactamase. In these experiments, all the bacteria trans-
formed with pNY01, pNY02 or pNY03 were selected and
grown in the presence of 10 mg/ml ampicillin. In this case,
the growth of cells results from the production in the periplas-
mic space of a correctly folded, functional and soluble
b-lactamase. The BlaP Thb/SmaI/Thb and BlaP Thr/CHBD/
Thr b-lactamases were overproduced in E. coli and the peri-
plasmic extracts from overnight cultures were loaded on a
HisTrapTM Chelating HP column. Thanks to the presence of a
polyhistidine tag at the C-terminal end of BlaP, the two pro-
teins were purified to homogeneity (Fig. 1C). After purifi-
cation, 40 mg of BlaP Thb/SmaI/Thb and 18 mg of BlaP Thb/
CHBD/Thb were obtained per litre of culture. In comparison,
no cytoplasmic and periplasmic productions were obtained
when we tried to express the isolated CHBD with the pET
expression systems (pET 26b and pET 28a) in E. coli BL21
DE3 derivatives strains [BL21 (DE3) 69 450-3; BL21 (DE3)
pLysS 69 451-3; OrigamiTM 2 (DE3) 71 345-3; RosettaTM
Tools to express and study proteins and their interactions
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(DE3) 70 954-3] at different temperatures (18, 28 and 378C).
In previous studies, CHBD was poorly expressed in E. coli as
a fusion protein with the GST (Ujita et al., 2003).
It has to be noticed that in our previous report
(Vandevenne et al., 2007), we pointed out a difference
(183 Da) between the theoretical and experimental molecular
weights of the chimeric protein. The nucleotide sequence
was verified and we did not find any mutation in the
sequence encoding the hybrid protein. To explain the
observed difference we also controlled the sequence of
the seven-histidine tag in which we found a substitution of
the first histidine to a proline and a deletion of the second
one resulting only on a five-histidine tag. But fortunately,
this probable recombination event did not perturb the purifi-
cation process.
As shown by Table I, no free thiol was detected with
BlaP Thb/CHBD/Thb by using Ellman’s reagent in denatur-
ing condition (6 M urea). This suggests that the six CHBD
cysteines of BlaP Thb/CHBD/Thb are involved in the for-
mation of three disulphide bounds. The same result was
obtained with purified CHBD. The literature indicates that
these disulphide bounds are of crucial importance for the
correct folding and thus the chitin binding activity of
CHBD (Tjoelker et al., 2000). The SDS–PAGE presented
in Fig. 2 are in agreement with these results because the
chitin binding activity of BlaP Thb/CHBD/Thb is comple-
tely inactivated in the presence of the reducing agent DTT.
BlaP Thb/SmaI/Thb was used as a negative control to
demonstrate the specificity of the interaction between BlaP
Thb/CHBD/Thb and chitin.









Glutathione 1.5 1.45 0.96 1
Glutathione 5 4.99 0.99 1
Glutathione 10 10.04 1 1
Glutathione 15 14.32 0.95 1
Glutathione 20 20.07 102 1
Glutathione 25 25.07 1 1
Glutathione 30 29.14 0.97 1
BlaP Thb-CHBD-Thb
BlaP
5 0.05 0.01 6
Thb/SmaI/Thb 5 0.13 0.03 0
CHBD 5 0.07 0.01 6
DTNB was used for determination of free thiols in denaturing condition
(6 M urea). Each protein was 5 mM. According to the sequences, the six
cysteins are located in CHBD. Consequently, the total concentration of free
SH groups is 30 mM. Standard solutions of glutathione were used to
calculated the percentage of free thiols. The ratios [SH]free/[Protein] and
[SH]th/[Protein] represent, respectively, the experimental and theorical
number of free cysteins. The first one is determined based on the absorbance
of DTNB solutions incubated with the proteins. The second one is
determined based on the amino acids sequence.
Fig. 1. Hybrid b-lactamase expression systems. (A) Construction of the expression vectors pNY02 and pNY03; (B) schematic representation of BlaP Thb/
SmaI/Thb; (C) SDS–PAGE analysis showing a Thrombin cleavage assay performed on purified BlaP Thb/SmaI/Thb. Lane 1 corresponds to the protein
molecular weight marker (Fermentas). Lane 2 corresponds to BlaP Thb/SmaI/Thb submitted to an overnight thrombin cleavage. Lane 3 corresponds to BlaP
Thb/SmaI/Thb. The arrows indicate the thrombin-cleavage sites.
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The Km and kcat values of the two purified hybrid
b-lactamases were compared with those of the native and
BlaP/SmaI enzymes (Table II). In regard to BlaP WT, it can
be concluded that the main impacts of the loop engineering
are 8- and 9-fold decreases of the kcat for BlaP Thb/CHBD/
Thb and BlaP Thb/SmaI/Thb, respectively. But these effects
can be considered as minor since they do not indicate signifi-
cant structural perturbations at the level of the BlaP active
site. This suggests also that the b-lactamase is correctly
folded and that the CHBD inserted polypeptide is well dis-
played at the surface of the carrier protein. We have observed
that the thrombin cleavage of BlaP Thb/SmaI/Thb (Fig. 1C)
does not yield an inactive b-lactamase. This observation is in
agreement with the data reported by Wehrman et al.
(Wehrman et al., 2002). The comparison of the kinetic par-
ameters between the cleaved and non-cleaved forms of BlaP
Thb/SmaI/Thb (Table II) shows no significant change in the
catalytic efficiency (kcat/Km) suggesting that the N-terminal
and C-terminal fragments of BlaP stay in close interaction
even after cleavage and that this complex is stabilised by
strong non-covalent interactions.
To explain this feature, we have analysed the crystallo-
graphic three-dimensional structure of BlaP WT [PDB entry
ID 4BLM (Moews et al., 1990)], and tried to identify the
interactions which bind the N-terminal to the C-terminal
parts of the protein. The Fig. 3A shows the structures of
BlaP wt and its two related fragments when the protein is
cleaved by thrombin. The side chains of the residues
involved in the enzymatic catalysis (Ser70, Lys73, Ser130,
Glu166, Asn 170 and Lys234) have been also represented.
Except for Lys234, they are all included in the N-terminal
fragment of BlaP. According to the literature, Lys234 could
be involved in the stabilisation of b-lactam in the catalytic
site during its hydrolysis (Jacob et al., 1990). Moreover, it
appears that the C-terminal fragment of BlaP also partici-
pates in the formation of the cavity harbouring the catalytic
site. If we refer to the structural organisation of class A
b-lactamases, the C-terminal fragment of BlaP participates
in the formation of the a/b domain of BlaP (Fig. 3B). This
domain is composed of an anti-parallel b-sheet and two anti-
parallel a-helices coming from the N- and C-extremities of
BlaP. The C-terminal fragment of BlaP bears three b-strands
of the b-sheet and one helix of the two anti-parallel
a-helices. Figure 3C highlights two features involving the
apolar side chains of the residues that compose the a/b
domain. The first is that hydrophobic interactions appear to
stabilised the anti-parallel a-helices. The second is that the
two anti-parallel a-helices are bound to the b-sheet by a
hydrophobic interface. The hydrogen bonds in the a/b
domain and the b-sheet alone are shown in Fig. 3D and E,
respectively. No hydrogen bond is established between the
two anti-parallel a-helices and between the anti-parallel
a-helices and the b-sheet. As expected, the five b-strands of
the b-sheet establish an important number of stabilising
hydrogen bonds. As mentioned early, three of the five
b-strands come from the C-terminal fragment of BlaP. Thus,
it is proposed that the two driving forces that stabilise the
protein complex after thrombin cleavage are due to both
hydrogen bonds and hydrophobic interactions.
The mutual affinity of the N-terminal and C-terminal frag-
ments of BlaP after thrombin cleavage and the presence of a
polyhistidine tag at the C-terminal end of BlaP constitute an
ideal opportunity to prepare pure CHBD polypeptides.
A two-step procedure has thus been validated (Fig. 4A) con-
sisting in a cleavage of BlaP Thb/CHBD/Thb with thrombin
in solution and followed by a depletion of the sample of
BlaP fragments by loading on a HisTrapTM Chelating HP
column. This step can be repeated until the desired level of
purity is obtained (Fig. 4B). Mass spectrometry analysis of
the depleted sample (Fig. 5) demonstrates the efficacy of the
system. Only CHBD is detected as monomeric and aggre-
gated forms. The monomeric form displays a molecular mass
of 9072 Da which corresponds exactly to the expected mass
after formation of the three disulphide bridges. The presence
of the aggregates is in agreement with the fact that solubility
problems arise upon concentration of CHBD domain when
devoid of its carrier. In comparison, purified CHBD could
not concentrated .0.25 mg/ml against .20 mg/ml of BlaP
Thb/ChBD/Thb (corresponding to 4 mg/ml of ChBD). This
shows that the b-lactamase carrier can increase the solubility
of protein fragments. The chitin binding assay presented on




Blap WT (378C) 35 1800 51
BlaP SmaI 48+1 1260+140 26+2




BlaPThb/CHBD/Thb 13.5+2.5 235+10 17+1
BlaP SmaI, BlaP Thb/SmaI/Thb, BlaP Thb/CHBD/Thb correspond to the
engineered forms of BlaP. The substrate was nitrocefin. The values are
compared with those reported for the wild-type enzyme BlaP WT (Matagne
et al., 1990).
Fig. 2. SDS–PAGE analysis showing chitin binding assays performed with purified BlaP Thb/SmaI/Thb, BlaP Thb/CHBD/Thb and CHBD. The proteins were
incubated in the presence of chitin. The free proteins in supernatants were analysed by SDS–PAGE. (2) corresponds to the supernatants before the addition of
chitin and (þ) corresponds to the supernatants after 2 h of incubation in the presence of chitin. To study the implication of disulphide bridges in the chitin
binding properties of CHBD, BlaP Thb/CHBD/Thb was preincubated in the presence of 50 mM DTT before the chitin binding assay.
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Fig. 3. Analysis of the BlaP WT crystallographic three-dimensional structure (PDB entry ID 4BLM, Moews et al., 1990). The lateral chain of the essential
active site residues Ser 70, Lys 73, Ser 130, Glu 166, Asn 170 and Lys 234 are shown. (A) Structures of BlaP WT and its two fragments after thrombin
cleavage. The side chains of residues directly involved in b-lactam hydrolysis are represented. (B) Structure of the a/b domain of BlaP WT. (C) Apolar side
chains of residues that compose the BlaP WT a/b domain. (D) Hydrogen bonds in the BlaP WT a/b domain. (E) Hydrogen bonds in the b-sheet of the BlaP
WT a/b domain.
Fig. 4. Preparation of purified CHBD. (A) schematic representation of the protocol used to prepare purified CHBD. (B) SDS–PAGE analysis showing the
different steps of the preparation of purified CHBD. Lane 1 and 4 corresponds to the protein molecular weight marker (Fermentas). Lane 2 corresponds to
purified BlaP Thb/CHBD/Thb. Lane 3 corresponds to the thrombin-cleaved BlaP Thb/CHBD/Thb. Lane 5 corresponds to the purified CHBD collected in the
flow through after loading of the sample on HisTrapTM Chelating HP. Lane 6 corresponds to the N-terminal and C-terminal fragments of BlaP Thb/CHBD/Thb
eluted with imidazole from the HisTrapTM column.
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Fig. 2 shows that the purified CHBD is still active. We also
determined the relative equilibrium association constant (Kr)
of CHBD to insoluble chitin, the calculated value is 8.5+
1 l g21 which is similar to that calculated for the hybrid
protein BlaPChBD namely 5.4+ 0.5 l g21.
Previously, we used the b-lactamase activity carried by
the hybrid protein BlaP CHBD to calculate the relative equi-
librium association constant (Kr) of CHBD to insoluble
chitin and to quantify the amount of bound protein by
measuring the free and immobilised b-lactamase activities.
These b-lactamase assays were performed with nitrocefin in
a colorimetric assay. In this work, we took advantage of this
feature to demonstrate that the BHP offers the opportunity to
screen therapeutic molecules. To validate this system, we
immunised a rabbit with the purified CHBD polypeptide
described above. The sera were collected after four injec-
tions. No seroneutralisation of the b-lactamase activity was
observed when BlaP Thb/CHBD/Thb was preincubated with
rabbit polyclonal preimmune and anti-CHBD sera. The
western blot presented on Fig. 6 indicates that anti-CHBD
antibodies have been induced after immunisation with the
purified CHBD and that these antibodies recognise free
CHBD, BlaP Thb/CHBD/Thb and the native human macro-
phage chitotriosidase. Figure 7 shows a seroneutralisation
titration curve of the chitin binding activity of BlaP Thr/
CHBD/Thr. The curve was obtained by plotting the percen-
tage of chitin-immobilised b-lactamase activity versus the
dilution of the tested sera. One hundred percent corresponds
to the chitin-immobilised b-lactamase activity in the absence
of the serum. These data show that immunisation with puri-
fied CHBD has induced anti-CHBD antibodies which can
prevent the interaction of CHBD with chitin.
Another application of our hybrid protein system is the
possibility to transpose it to phage display technology. The
hybrid b-lactamase BlaPChBD can be successfully expressed
at the surface of phages so that phage particles retain a
b-lactamase activity which is used to monitor phage/ligand
interactions. Figure 8 illustrates the b-lactamase activity
immobilised on chitin powder and shows that this interaction
is specific.
Finally, Fig. 9 shows the interaction of purified BlaPChBD
with a pathogenic fungi such as C. albicans. The monitoring
of the immobilised b-lactamase activity on this micro-
organism demonstrates that our hybrid protein is able to
interact with chitin present in fungal cell wall and thus can
be used for diagnosis fungal infections.
Discussion
During the last decade, the class A b-lactamases have
emerged as promising reporter enzymes to study protein
interactions. These proteins are attractive enzymes because
they are monomeric and of small size (Philippon et al., 1998).
Fig. 5. Mass spectrometry analysis of the purified CHBD. The majority form is the monomer. Arrows represent the multimerisation of ChBD due to
aggregation phenomenon.
Fig. 6. Immunodetection of CHBD. The western blot was performed with
rabbit anti-CHBD serum. Lanes 1, 2 and 3 were obtained with purified BlaP
THb/CHBD/Thb, CHBD and human macrophage chitotriosidase.
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Their three-dimensional structures are well-defined and they
are classified as very efficient enzymes (Matagne et al.,
1999). b-lactamase activity is also highly specific with no
equivalent in eukaryotic cells and production of b-lactamase
by these cells does not result in toxic effects (Matagne et al.,
1998; Philippon et al., 1998; Galarneau et al., 2002). These
proteins have been expressed successfully in prokaryotic and
eukaryotic cells allowing their utilisations as well for in vitro
as in vivo applications (Galarneau et al., 2002). A massive
expression of these enzymes can be obtained with prokaryo-
tic expression systems allowing to drastically reduce their
production times and costs (Frate et al., 2000). A large
variety of b-lactam substrates has been developed including
chromogenic b-lactams for immunoassay, fluorescein
membrane-permeant b-lactams which allow cell imagery,
flow cytometry and gene expression assay, and non-toxic
b-lactam prodrugs for antibody-directed enzyme prodrug
therapy (Bebrone et al., 2001; Vrudhula et al., 2003; Lee
et al., 2005; Naqvi and Singh, 2007). For this latter appli-
cation, a mutated b-lactamase with reduced immunogenicity
has been developed (Harding et al., 2005).
Many applications have been reported in the literature. For
example, genetic insertion of small peptides into loops bor-
dering the active site of b-lactamase was also used to create
allosteric regulatable enzyme for homogeneous immunoas-
says (Legendre et al., 1999). A common permissive-insertion
site in class A b-lactamase has been used to insert random
gene fragments. When combined with phage display, this
modified enzyme has been used for epitope mapping
(Chevigne´ et al., 2007), immunoassay development and
vaccine development (Ruth et al., 2005). Assays based on
the complementation of b-lactamase fragments fused to
interacting polypeptides that regenerate enzymatic activity
were used to monitor inducible protein–protein interactions
in eukaryotic cells (Galarneau et al., 2002; Wehrman et al.,
2002; Qureshi, 2007). The hydrolysis of b-lactams generates
protons so that the b-lactamases are employed for the devel-
opment of potentiometric signal transduction in biosensors
(article submitted for publication). These examples show that
b-lactamases have been successfully utilised in a wide range
of applications.
This work contributes to enlarge the application fields of
b-lactamase by proposing an original tool that elicits the pro-
duction of difficult to express protein fragments and facili-
tates their purifications and studies. In a first step, this
approach delivers purified hybrid proteins in which the
Fig. 9. Detection of fungal chitin contained in an overnight culture of
Candida albicans. The cells are recovered by centrifugation of the culture
and washed twice with 50 mM sodium phosphate buffer pH 7.5. The cell
suspensions were then incubated 2 h with 25 pmol of each protein in 500 ml
of 50 mM sodium phosphate buffer pH 7.5, 150 mM NaCl. After removing
the supernatant, the cell pellets were washed three times and then incubated
for 35 min with 1 ml of nitrocefin (100 mM). After filtration of the
suspension, absorbance of the nitrocefin hydrolysis product was measured at
482 nm. A control of a suspension of C. albicans cells have been performed.
Fig. 8. Binding assay mixtures contained 10 mg (dry weight) of insoluble
chitin and 100 ml of phage particle solutions (DO265 nm ¼ 5) in 500 ml of
50 mM sodium Tris buffer, 150 mM NaCl (pH 7.5). Assay mixtures were
incubated for 2 h at room temperature for binding. After removing the
supernatant, the pellet was washed three times and then incubated for 2 min
with 1 ml of nitrocefin (100 mM). After filtration of the suspension,
absorbance of the nitrocefin hydrolysis product was measured at 482 nm.
Fig. 7. Seroneutralisation curve assays of CHBD. The binding of BlaP Thb/
CHBD/Thb is monitored by measuring the immobilised b-lactamase activity
to chitin. Nitrocefin is used as substrate. BlaP Thb/CHBD/Thb is
preincubated with increasing dilutions of serum before addition of chitin.
The percentage of immobilised b-lactamase activity is plotted versus the
dilution of the serum. One hundred percent corresponds to the immobilised
b-lactamase activity obtained in the absence of serum.
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protein fragments of interest are each displayed into a repor-
ter enzyme, BlaP. Thanks to the presence of the carrier
protein, the binding properties of the protein fragments can
be studied by using the b-lactamase activity. To allow the
study of the properties of the insert independently of the pre-
sence of the carrier, two specific protease-recognition sites
surrounding the insert have been introduced into the hybrid
protein. By combining specific proteolytic cleavage and affi-
nity chromatography, a purified insert was isolated. No
residual trace of the carrier was detected by mass spec-
trometry after purification. We have demonstrated that the
purified insert deleted of its carrier protein retained its bio-
logical properties. Moreover we showed that the use of the
b-lactamase carrier system can be successfully used to
enhance peptide expression in E. coli but also to increase
protein solubility during sample concentration.
In a second step, we have showed that the hybrid
b-lactamase is an efficient tool in the screening of molecules
which can neutralise the biological properties of the studied
protein fragment. In this work, the purified insert was used to
immunise a rabbit and the collected polyclonal serum was
shown to inhibit the binding properties of the insert by moni-
toring the binding of the hybrid protein to its specific ligand.
This was done by measuring the immobilised b-lactamase
activity. This approach can be extended to drug discovery of
molecule enable to prevent or to elicit specific interactions.
We also showed that this system can be used to detect
fungal infections and also easily transposed to phage display
technology. This approach can be applied to the screening of
enzyme-coupled protein binding domains which can also be
overexpressed as recombinant proteins and directly
implemented in immunoassays. This method is advantageous
for affinity maturation of protein domains because the
b-lactamase activity of phage particles allows the monitoring
of the affinity maturation during the enrichments steps or the
comparison of affinities of individual mutants without the
necessity to produce a purified recombinant protein.
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